Xenon Pharmaceuticals Inc. News Releases http://investor.xenon-pharma.com/ Xenon Pharmaceuticals Inc. News Releases en Xenon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update http://investor.xenon-pharma.com/news-releases/news-release-details/xenon-pharmaceuticals-reports-first-quarter-2019-financial Company Reports Advancements in Neurology-Focused Pipeline and Anticipates Multiple Products in  Phase 2 or Later Stage Development this Year Conference Call at 4:30 pm ET Today BURNABY, British Columbia , May 07, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. Tue, 07 May 2019 16:01:00 -0400 Xenon Pharmaceuticals Inc. News Releases 9576 Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Provide Corporate Update http://investor.xenon-pharma.com/news-releases/news-release-details/xenon-pharmaceuticals-host-conference-call-and-webcast-18 BURNABY, British Columbia , April 30, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2019 financial and operating results after the close of U.S. Tue, 30 Apr 2019 16:01:00 -0400 Xenon Pharmaceuticals Inc. News Releases 9566 Xenon Pharmaceuticals to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference http://investor.xenon-pharma.com/news-releases/news-release-details/xenon-pharmaceuticals-present-2019-bloom-burton-co-healthcare BURNABY, British Columbia , April 24, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone , Xenon's Chief Executive Officer, will present a corporate update at the Bloom Burton & Co. Wed, 24 Apr 2019 16:01:00 -0400 Xenon Pharmaceuticals Inc. News Releases 9531 Xenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate Update http://investor.xenon-pharma.com/news-releases/news-release-details/xenon-pharmaceuticals-reports-2018-financial-results-and Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019 Global XEN1101 Phase 2b Clinical Trial Underway with Data Anticipated in Second Half of 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia , March 06, 2019 (GLOBE NEWSWIRE) -- Xenon Wed, 06 Mar 2019 16:01:00 -0500 Xenon Pharmaceuticals Inc. News Releases 9416 Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2018 Financial Results and Provide Corporate Update http://investor.xenon-pharma.com/news-releases/news-release-details/xenon-pharmaceuticals-host-conference-call-and-webcast-17 BURNABY, British Columbia , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2018 financial and operating results after the close of U.S. financial markets on Wednesday, March 6, 2019 . Wed, 27 Feb 2019 16:01:00 -0500 Xenon Pharmaceuticals Inc. News Releases 9411 Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures http://investor.xenon-pharma.com/news-releases/news-release-details/behind-seizuretm-program-expansion-helps-speed-diagnosis-genetic Behind the Seizure™ Program Expansion Helps Speed the Diagnosis  of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures — Stoke Therapeutics and Xenon Pharmaceuticals Join  Founders BioMarin and Invitae to Offer a No-Cost Epilepsy Gene Panel Testing  Program for Children Up to 60 Tue, 26 Feb 2019 04:35:00 -0800 Xenon Pharmaceuticals Inc. News Releases 9471 Xenon Provides Key Regulatory Updates on XEN007 and XEN1101 http://investor.xenon-pharma.com/news-releases/news-release-details/xenon-provides-key-regulatory-updates-xen007-and-xen1101 FDA Grants Rare Pediatric Disease Designation to XEN007 for Alternating Hemiplegia of Childhood (AHC); Xenon Eligible to Apply for Priority Review Voucher IND for XEN1101 Accepted; Site Selection and Patient Enrollment Underway in Canada and the United States for XEN1101 Phase 2b Clinical Trial Mon, 28 Jan 2019 08:01:11 -0500 Xenon Pharmaceuticals Inc. News Releases 9366 Xenon Pharmaceuticals Outlines 2019 Key Milestones http://investor.xenon-pharma.com/news-releases/news-release-details/xenon-pharmaceuticals-outlines-2019-key-milestones Innovative Product Pipeline Includes Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019 BURNABY, British Columbia , Jan. 06, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today provided Sun, 06 Jan 2019 21:00:36 -0500 Xenon Pharmaceuticals Inc. News Releases 9361 Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual Meeting http://investor.xenon-pharma.com/news-releases/news-release-details/xenon-announces-final-results-xen1101-phase-1-clinical-trial-and XEN1101 CTA Accepted by Health Canada for Initiation of Phase 2 Clinical Trial in Adult Focal Epilepsy; U.S. IND Filing Targeted in Q1 2019 Conference Call to Discuss Xenon’s Epilepsy Programs at 9 am ET Today BURNABY, British Columbia , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. Mon, 03 Dec 2018 07:30:32 -0500 Xenon Pharmaceuticals Inc. News Releases 9311 Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of Presentations at the 2018 American Epilepsy Society (AES) Meeting http://investor.xenon-pharma.com/news-releases/news-release-details/xenon-pharmaceuticals-host-conference-call-and-webcast-provide-1 BURNABY, British Columbia , Nov. 30, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Monday, December 3, 2018 at 9:00 am Eastern Time ( 6:00 am Pacific Time ) Fri, 30 Nov 2018 09:01:01 -0500 Xenon Pharmaceuticals Inc. News Releases 9306